Result of General Meeting

Neuropharm Group plc (AIM: NPH) confirms that at the General Meeting held earlier today, the Resolution set out in the circular sent to shareholders on 20 April 2010 to effect a winding up of the Company by way of a members’ voluntary liquidation (”MVL”) and the cancellation of admission to trading of the Company’s securities on AIM was duly passed. Cancellation of admission is therefore expected to occur at 7.00 a.m. tomorrow, 19 May 2010. The result of the General Meeting was 21,975,056 votes in favour of the Resolution, no votes against and no abstentions.

Following the General Meeting, the appointment of Samantha Jane Keen and Ian Carr of Grant Thornton UK LLP, No 1 Dorset Street, Southampton SO15 2DP as joint liquidators of the Company (the “Liquidators”) is now effective. The Liquidators will be responsible for dealing with the conduct of the MVL and the determination of the timing and amount of any distribution(s) to Shareholders. A Q&A relating to the liquidation process will be posted on the Company’s website at www.neuropharm.co.uk.

Enquiries

For further information please contact:

Neuropharm + 44 (0) 1372 371 171

Robert Mansfield , Chief Executive Officer

Graham Yeatman, Chief Financial Officer

Grant Thornton UK LLP + 44 (0) 2380 381 100

Samantha Keen

Ian Carr

Piper Jaffray Ltd. + 44 (0) 20 3142 8700

Neil Mackison , Rupert Winckler

Notes to Editors:

About Neuropharm

Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.